Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-866949 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BMS-866949 (Panel 1) | EXPERIMENTAL | - |
| BMS-866949 (Panel 2) | EXPERIMENTAL | - |
| BMS-866949 (Panel 3) | EXPERIMENTAL | - |
| BMS-866949 (Panel 4) | EXPERIMENTAL | - |
| BMS-866949 (Panel 5) | EXPERIMENTAL | - |
| BMS-866949 (Panel 6) | EXPERIMENTAL | - |
| BMS-866949 (Panel 7) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-866949 | DRUG | (Panel 1 - 0.5 mg) - Oral Solution, Oral, once, 14 days |
| Placebo | DRUG | (Matching volume) - Oral Solution, Oral, once 14 days |
Inclusion Criteria: * Healthy male 18-55 * Women not of child bearing potential, 18-55 Exclusion Criteria: * History of or current treatment for psychiatric illnesses, substance abuse or dependence * History of a clinically significant neurological disorder (e.g., history of stroke, head trauma, ...
BMS-866949 is an investigational small molecule being developed for the treatment of depression. It is in Phase 1 clinical development, meaning it is still being studied and has not been approved for any use. The drug is being evaluated for its safety, pharmacokinetics, and pharmacodynamics in clinical trials.
BMS-866949 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the drug's safety and pharmacological properties in healthy subjects.
BMS-866949 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical research for the treatment of depression.
BMS-866949 has one completed clinical trial, identified as NCT00949767. This Phase 1 study, titled "Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects," was conducted in Sweden with 64 participants. The trial was randomized, double-blind, and controlled, enrolling healthy volunteers aged 18 years and older.
BMS-866949 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for depression. The completed Phase 1 trial focused on safety and pharmacological parameters in healthy subjects, and the drug has not yet progressed to later-stage trials or regulatory approval.